deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT00777036

A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

A Phase II Study of Dasatinib Therapy in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or With Ph+ Leukemias Resistant or Intolerant to Imatinib

Sponsor: Bristol-Myers Squibb

Conditions Leukemia
Interventions Dasatinib
Updated 21 times since 2017 Last updated: Aug 12, 2025 Started: Mar 20, 2009 Primary completion: Sep 1, 2016 Completion: Jan 27, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Leukemia and is currently completed. Bristol-Myers Squibb leads this study, which shows 21 recorded versions since 2009 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Jan 2018 · 4 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Mar 2022 · 5 months · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Dec 2022 · 5 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Mar 2023 · 59 days · monthly snapshot~Mar 2023 – ~Jul 2023 · 4 months · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Oct 2023 · 2 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Apr 2025 — Sep 2025 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Sep 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Oct 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 16 earlier versions

  1. Aug 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Jul 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE2

  3. Mar 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Jan 2023 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE2

  6. Jul 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE2

  7. Jun 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE2

  8. May 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE2

  9. Mar 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Unknown Status → Active Not Recruiting

  10. Oct 2021 — Mar 2022 [monthly]

    Unknown Status PHASE2

    Status: Active Not Recruiting → Unknown Status

  11. Jan 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2

  12. Jun 2018 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  13. Jan 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  14. Sep 2017 — Jan 2018 [monthly]

    Active Not Recruiting PHASE2

  15. Feb 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE2

  16. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Aurora, United States , Bangalore, India , Barcelona, Spain , Birmingham, United Kingdom , Birmingham, United States , Bloemfontein, South Africa , Bologna, Italy , Boston, United States , Bucharest, Romania and 68 more locations